SCHEDULE: FMR LLC & Abigail Johnson Report 3.9% Zai Lab Stake

FMR LLC and Abigail P. Johnson disclose a 3.9% beneficial ownership stake in Zai Lab Ltd. common stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 43,535,993 shares of Zai Lab Ltd. common stock.
• This ownership represents 3.9% of the total class of Zai Lab Ltd. securities.
• FMR LLC holds sole voting and dispositive power over all 43,535,993 shares.
• Abigail P. Johnson, as Director, Chairman, and Chief Executive Officer of FMR LLC, is also deemed to have dispositive power over these shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a change from previous ownership disclosures.
• FMR LLC is classified as a parent holding company, and Abigail P. Johnson is an individual reporting person.
• The Johnson family, including Abigail P. Johnson, are predominant owners of FMR LLC, forming a controlling group with 49% of the voting power.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure. While FMR LLC maintains a substantial stake, the reduction below 5% (implied by Amendment No. 3) could signal a rebalancing or slight decrease in conviction, but it's not inherently negative without further context on the reasons for the change.

Positives

• FMR LLC, a major institutional investor, maintains a significant beneficial ownership stake of 3.9% in Zai Lab Ltd., indicating continued interest.

Negatives

• The ownership percentage of 3.9% is below the 5% threshold, which, if it represents a reduction from a previous higher stake (implied by Amendment No. 3), could suggest a portfolio rebalancing or a slight decrease in conviction by the institutional investor.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into major investors' positions. FMR LLC, a prominent asset manager, maintaining a significant, albeit potentially re-evaluated, stake in Zai Lab Ltd. suggests continued, though possibly adjusted, confidence in the biotechnology or pharmaceutical sector, particularly in companies focused on innovative therapies.

Comparison to Industry Standards

• A 3.9% stake is a notable position for an institutional investor like FMR LLC, though it falls below the 5% threshold that typically triggers more stringent reporting requirements and potential influence over corporate actions.
• Compared to other major institutional investors who often hold larger, sometimes activist, stakes (e.g., Vanguard or BlackRock often hold 5-10%+ in many large-cap companies for passive index tracking), FMR LLC's current position in Zai Lab Ltd. appears to be a more strategic, non-controlling investment.
• The structure, where a parent holding company (FMR LLC) and its CEO (Abigail P. Johnson) jointly report, is standard for large asset management firms, reflecting the consolidated control over managed assets.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Management: Awareness of a major shareholder's position, though below a control threshold, is important for investor relations.

Key Dates

Recommendation

This Schedule 13G Amendment No. 3 discloses FMR LLC's and Abigail P. Johnson's beneficial ownership in Zai Lab Ltd. at 3.9%. While this represents a continued significant institutional interest, the reduction below the 5% threshold (implied by Amendment No. 3) could be interpreted by the market as a rebalancing or a slight decrease in conviction. However, without further context on the reasons for the change or new operational data from Zai Lab Ltd., a 'hold' recommendation is appropriate, advising investors to monitor future company developments and FMR LLC's subsequent filings.

Keywords

ZAI LAB LTD, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management